Hindering triple negative breast cancer progression by targeting endogenous interleukin-30 requires IFNγ signaling.
Carlo SorrentinoStefania Livia CiummoLuigi D'AntonioPaola LanutiScott I AbramsZhinan YinLi-Fan LuEmma Di CarloPublished in: Clinical and translational medicine (2021)
IL30mRNA expression is associated with the TNBC subtype. IL30 boosts proliferation and migration of TNBC cells and reshapes their immunity gene expression profile. The lack of endogenous IL30 hinders TNBC growth and progression and prolongs host survival. TNBC growth inhibition, due to the lack of endogenous IL30, requires INFγ production by T and NK cells.